Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Table 1 MK-2206 treatment regimen by treatment arm

Treatment arm	MK-2206 dose, mg	Schedule^a	Combination with:
1	45	QOD	Carboplatin (IV, AUC6, 1-hour infusion) and paclitaxel (IV, 200 mg/m², 3-hour infusion)
	60	QOD
	90	Q3W
	135
	200
2	45	QOD	Docetaxel (IV, 75 mg/m², 1-hour infusion)
	90	Q3W	Docetaxel (IV, 60 mg/m², 1-hour infusion)
	135
	200
3	45	QOD*	Erlotinib (oral, 100 mg, QD)
	45	QOD*	Erlotinib (oral, 150 mg, QD)
	135	QW	Erlotinib (oral, 100 mg, QD)
	135		Erlotinib (oral, 150 mg, QD)

Abbreviations: IV intravenous, AUC6 area under the curve 6.0 mg/mL, QD once daily.
^aQOD = once every other day on days 1, 3, 5, and 7 of 21-day cycle, except *: alternate day dosing on days 1–21; Q3W = once every 3 weeks on day 1 of 21-day cycle; QW = once weekly on days 1, 8, and 15 of 21-day cycle.

ISSN: 1756-8722